- Home
- LOW vs GILD Comparison
LOW vs GILD Comparison
Compare LOW & GILD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LOW
- GILD
- Stock Information
- Founded
- LOW 1946
- GILD 1987
- Country
- LOW United States
- GILD United States
- Employees
- LOW N/A
- GILD N/A
- Industry
- LOW RETAIL: Building Materials
- GILD Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- LOW Consumer Discretionary
- GILD Health Care
- Exchange
- LOW Nasdaq
- GILD Nasdaq
- Market Cap
- LOW 133.5B
- GILD 147.6B
- IPO Year
- LOW N/A
- GILD 1992
- Fundamental
- Price
- LOW $242.48
- GILD $125.95
- Analyst Decision
- LOW Buy
- GILD Buy
- Analyst Count
- LOW 20
- GILD 22
- Target Price
- LOW $273.15
- GILD $123.45
- AVG Volume (30 Days)
- LOW 3.5M
- GILD 7.8M
- Earning Date
- LOW 11-19-2025
- GILD 10-30-2025
- Dividend Yield
- LOW 1.99%
- GILD 2.48%
- EPS Growth
- LOW 0.70
- GILD 6514.05
- EPS
- LOW 12.06
- GILD 6.42
- Revenue
- LOW $84,255,000,000.00
- GILD $29,087,000,000.00
- Revenue This Year
- LOW $2.74
- GILD $3.05
- Revenue Next Year
- LOW $6.25
- GILD $3.29
- P/E Ratio
- LOW $20.03
- GILD $19.85
- Revenue Growth
- LOW 0.64
- GILD 2.79
- 52 Week Low
- LOW $206.39
- GILD $88.57
- 52 Week High
- LOW $280.64
- GILD $128.70
- Technical
- Relative Strength Index (RSI)
- LOW 57.00
- GILD 55.79
- Support Level
- LOW $228.73
- GILD $124.49
- Resistance Level
- LOW $243.05
- GILD $128.16
- Average True Range (ATR)
- LOW 5.40
- GILD 3.18
- MACD
- LOW 1.96
- GILD 0.02
- Stochastic Oscillator
- LOW 97.11
- GILD 74.76
About LOW Lowe's Companies Inc.
Lowe's is the second-largest home improvement retailer globally, with around 1,750 stores in the US, after the 2023 divestiture of its Canadian locations (RONA, Lowe's Canada, Réno-Dépôt, and Dick's Lumber). The firm's stores offer products and services for home decorating, maintenance, repair, and remodeling, with maintenance and repair accounting for two-thirds of products sold. Lowe's primarily targets retail do-it-yourself (around 70% of sales) and do-it-for-me customers, but has expanded its professional business clients to 30% from less than 20% in the past six years (set ot expand further with the acquisition of FBM). We estimate Lowe's captures a high-single-digit share of the domestic home improvement market, based on US Census data and management's market size estimates.
About GILD Gilead Sciences Inc.
Gilead Sciences develops and markets therapies to treat and prevent life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).